ResMed (RMD) to Release Quarterly Earnings on Thursday

ResMed (NYSE:RMD - Get Free Report) is expected to be issuing its Q4 2025 quarterly earnings data after the market closes on Thursday, July 31st. Analysts expect ResMed to post earnings of $2.47 per share and revenue of $1.33 billion for the quarter.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 26.15% and a return on equity of 25.67%. The business had revenue of $1.29 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the previous year, the firm earned $2.13 EPS. The business's revenue for the quarter was up 7.9% compared to the same quarter last year. On average, analysts expect ResMed to post $9 EPS for the current fiscal year and $10 EPS for the next fiscal year.

ResMed Price Performance

NYSE:RMD traded up $0.06 during mid-day trading on Thursday, hitting $273.43. 880,777 shares of the company's stock traded hands, compared to its average volume of 836,567. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.49 and a current ratio of 3.41. The company has a market cap of $40.09 billion, a PE ratio of 30.69, a price-to-earnings-growth ratio of 1.70 and a beta of 0.77. The firm's 50 day simple moving average is $253.23 and its 200 day simple moving average is $238.57. ResMed has a 1 year low of $196.43 and a 1 year high of $274.00.

Insider Buying and Selling

In other ResMed news, Director Witte Jan De sold 2,000 shares of ResMed stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $243.47, for a total transaction of $486,940.00. Following the transaction, the director directly owned 5,806 shares of the company's stock, valued at $1,413,586.82. The trade was a 25.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction on Monday, July 7th. The stock was sold at an average price of $256.72, for a total transaction of $2,056,070.48. Following the completion of the sale, the chief executive officer directly owned 455,503 shares of the company's stock, valued at $116,936,730.16. The trade was a 1.73% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,013 shares of company stock valued at $7,238,913. 0.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ResMed

A hedge fund recently raised its stake in ResMed stock. Jones Financial Companies Lllp grew its position in shares of ResMed Inc. (NYSE:RMD - Free Report) by 52.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,882 shares of the medical equipment provider's stock after purchasing an additional 994 shares during the period. Jones Financial Companies Lllp's holdings in ResMed were worth $645,000 as of its most recent SEC filing. 54.98% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on RMD. Mizuho upped their target price on ResMed from $250.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. JPMorgan Chase & Co. increased their price objective on ResMed from $286.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, April 24th. Morgan Stanley set a $286.00 price objective on ResMed and gave the stock an "overweight" rating in a research report on Tuesday, May 20th. UBS Group reduced their target price on shares of ResMed from $290.00 to $285.00 and set a "buy" rating on the stock in a report on Thursday, April 24th. Finally, Royal Bank Of Canada raised shares of ResMed from a "sector perform" rating to an "outperform" rating and raised their price target for the stock from $255.00 to $294.00 in a research note on Tuesday, July 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $263.00.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.